These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 26549695)

  • 21. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
    Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
    JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obeticholic Acid: First Global Approval.
    Markham A; Keam SJ
    Drugs; 2016 Aug; 76(12):1221-6. PubMed ID: 27406083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Old and new treatments for primary biliary cholangitis.
    Chascsa D; Carey EJ; Lindor KD
    Liver Int; 2017 Apr; 37(4):490-499. PubMed ID: 28371104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Management of Primary Biliary Cholangitis-Strategies and Evolving Trends.
    Gao L; Wang L; Woo E; He X; Yang G; Bowlus C; Leung PSC; Gershwin ME
    Clin Rev Allergy Immunol; 2020 Oct; 59(2):175-194. PubMed ID: 31713023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effective treatment of autoimmune hepatitis-primary biliary cholangitis overlap syndrome with obeticholic acid.
    Castro Limo JD; Romero-Gutiérrez M; Ruiz Martín J
    Rev Esp Enferm Dig; 2020 Sep; 112(9):737. PubMed ID: 32496125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of cholestatic disease in 2017.
    de Vries E; Beuers U
    Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current Treatment Options for Primary Biliary Cholangitis.
    Wong KA; Bahar R; Liu CH; Bowlus CL
    Clin Liver Dis; 2018 Aug; 22(3):481-500. PubMed ID: 30259848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis.
    Panzitt K; Jungwirth E; Krones E; Lee JM; Pollheimer M; Thallinger GG; Kolb-Lenz D; Xiao R; Thorell A; Trauner M; Fickert P; Marschall HU; Moore DD; Wagner M
    J Hepatol; 2020 Jun; 72(6):1122-1131. PubMed ID: 32001325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis.
    Kulkarni AV; Tevethia HV; Arab JP; Candia R; Premkumar M; Kumar P; Sharma M; Reddy DN; Padaki NR
    Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101675. PubMed ID: 33722778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New name and new treatments for primary biliary cholangitits].
    Bossen L; Ytting H; Jepsen P; Hamberg O; Ott P; Grønbæk H
    Ugeskr Laeger; 2018 Mar; 180(10):. PubMed ID: 29536837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current and potential treatments for primary biliary cholangitis.
    Shah RA; Kowdley KV
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):306-315. PubMed ID: 31806572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Modern treatment of primary biliary cholangitis].
    Strassburg CP
    Internist (Berl); 2018 Jan; 59(1):105-112. PubMed ID: 29110023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders.
    Fiorucci S; Di Giorgio C; Distrutti E
    Handb Exp Pharmacol; 2019; 256():283-295. PubMed ID: 31201552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Farnesoid X receptor agonists for primary biliary cirrhosis.
    Lindor KD
    Curr Opin Gastroenterol; 2011 May; 27(3):285-8. PubMed ID: 21297469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Primary biliary cholangitis].
    Soret PA; Chazouillères O; Corpechot C
    Rev Prat; 2021 Oct; 71(8):885-891. PubMed ID: 35147347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrates for Primary Biliary Cholangitis: What's All the Hype?
    Levy C
    Ann Hepatol; 2017; 16(5):704-706. PubMed ID: 28809729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current Landscape and Evolving Therapies for Primary Biliary Cholangitis.
    Fiorucci S; Urbani G; Di Giorgio C; Biagioli M; Distrutti E
    Cells; 2024 Sep; 13(18):. PubMed ID: 39329760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The challenges of primary biliary cholangitis: What is new and what needs to be done.
    Terziroli Beretta-Piccoli B; Mieli-Vergani G; Vergani D; Vierling JM; Adams D; Alpini G; Banales JM; Beuers U; Björnsson E; Bowlus C; Carbone M; Chazouillères O; Dalekos G; De Gottardi A; Harada K; Hirschfield G; Invernizzi P; Jones D; Krawitt E; Lanzavecchia A; Lian ZX; Ma X; Manns M; Mavilio D; Quigley EM; Sallusto F; Shimoda S; Strazzabosco M; Swain M; Tanaka A; Trauner M; Tsuneyama K; Zigmond E; Gershwin ME
    J Autoimmun; 2019 Dec; 105():102328. PubMed ID: 31548157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obeticholic acid (Ocaliva) for primary biliary cholangitis.
    Med Lett Drugs Ther; 2017 Mar; 59(1517):53-55. PubMed ID: 28323811
    [No Abstract]   [Full Text] [Related]  

  • 40. Emerging drugs for the treatment of primary biliary cholangitis.
    Phaw NA; Dyson JK; Jones D
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):101-112. PubMed ID: 32253941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.